Risk factor for relapse in pemphigus patients treated with rituximab

분야: 의약학 > 피부과학
저자: ( Ji Won Kim ) , ( Ji Soo Lim ) , ( Soo Ick Cho ) , ( Jin Ho Chung )
발행기관: 대한피부과학회
간행물정보: 프로그램북(구 초록집) 2017년, 제69권 제2호, 396(총1페이지)
파일형식: 27735701.pdf [무료 PDF 뷰어 다운로드]
※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
구매가격: 1,000원
적립금: 30원 (구매자료 3% 적립)

연관 논문

Risk Factors for Rituximab-Induced Interstitial Lung Diseases in Patients with Malignant Lymphoma

P092 : Adjuvant rituximab treatment for pemphigus: a retrospective study of 45 patients in a single-center with long-term follow-up

FCT 8 : Adjuvant Rituximab Therapy of Pemphigus: A retrospective study of 56 patients in a single-center

ORIGINAL ARTICLE : Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients

Original Article : Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma

영문초록

Background: Many studies reported the outcome of rituximab use in pemphigus, but studies on clinical risk factors affecting clinical outcome or relapse are insufficient.
Objectives: The purpose of this study was to find out the clinical outcome and risk factor of relapse in patients diagnosed with pemphigus and treated with rituximab.
Methods: A retrospective chart analysis was performed on pemphigus patients who were treated with rituximab in the dermatology clinic of Seoul National University Hospital.
Results: A total of 40 patients with pemphigus were treated with rituximab, of which 39 had remission. Twenty-seven patients were treated with less than 2 infusions, while 13 patients were treated with more than 3 infusions. Among them, 24 patients showed complete remission, 15 patients showed partial remission, and 1 patient died during treatment. The most important clinical factor affecting remission and recurrence was the presence of mucosal lesions. The risk of relapse was 4.2 times higher in patients with mucosal lesions than in those without (p= 0.039). There was no statistically significant difference in sex, age, type of pemphigus, number of rituximab infusion (less than 2 or more than 3 infusions), disease duration, and severity score.
Conclusion: In pemphigus patients treated with rituximab, presence of mucosal lesions resulted in poor clinical outcome and frequent recurrence. Therefore, pemphigus patients with mucosal lesions should consider more aggressive treatment.

#Rituximab # Pemphigus # Relapse # Remission # Mucous membrane

추천자료

[의학과] 신장 Student Case Conference

[정신건강] 조울증(bipolar disorder)

[의학][내과]-신장-nephrotic syndrome

내과신장학 레포트

[의대 본과 pk 실습] 심낭염의 종류 및 발생기전, 대동맥류의 분류, 진단 및 치료법

영문 개 명작의 스토리 작가의 전깃줄 거리 주제 등장인물 리포트

의대 본과 4학년 PK과제 TOPICDERMATITIS

의대 본과 4학년 PK과제 Emergency Treatment of Asthma

[상담심리학] 약물 및 알코올 중독에 대한 상담(영문)

[정보탐색]위암(gastric cancer)을 줄이기 위한 Helicobacter pylor의 제거시술(eradication)효과의 평가